Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Fuling Central Hospital of Chongqing City
Modality
UNKNOWN
Development Phase
Phase 2/3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
46Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02575092CT.gov The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and Treatment | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diabetic Kidney Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Enalapril Maleate (this asset) | Fuling Central Hospital of Chongqing City | P2/3 | B · 61 |
| Folic Acid | Fuling Central Hospital of Chongqing City | P2/3 | BB |
| Valsartan | Columbia University | P4 | BB |
| Spironolactone | Hospital de Messejana Dr. Carlos Alberto Studart Gomes | P4 | BB |
| Lisinopril | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P3 | BB |
| Nifedipine | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P3 | BB |
| Simvastatin | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P3 | BB |
| Finerenone | Hospital de Messejana Dr. Carlos Alberto Studart Gomes | P4 | B |
| Semaglutide | Geisinger Clinic | P3 | B |
+9 more in the Diabetic Kidney Disease cohort
Other indications for Enalapril Maleate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hyperhomocysteinemia | — | P4 | BB · 69 |
| Essential Hypertension | — | P4 | BB · 67 |
| Hypertensive Disorder | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Folic AcidFuling Central Hospital of Chongqing CityBB
- ValsartanColumbia UniversityBB
- SpironolactoneHospital de Messejana Dr. Carlos Alberto Studart GomesBB
- LisinoprilNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)BB
- NifedipineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)BB
Citation
Floatz Terminal. Enalapril Maleate in Diabetic Kidney Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/enalapril-maleate-diabetic-kidney-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →